Non-alcoholic fatty liver disease in the metabolic syndrome

Guiseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis, Piero Portincasa

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)2193-2198
Number of pages6
JournalCurrent Pharmaceutical Design
Issue number21
StatePublished - Jul 2007


  • Breath test
  • Metabolic syndrome
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Non-alcoholic fatty liver disease in the metabolic syndrome'. Together they form a unique fingerprint.

Cite this